Kazia Therapeutics launches registered public offering of ADSs and warrants

• Kazia launched a tranched registered public offering of ADSs, or pre-funded warrants in lieu of ADSs.
• Deal includes Series A warrants priced at 115% of the offering price, expiring after the Stage IV TNBC readout or five years.
• Series B warrants priced at 125% of the offering price, expiring after the HR+/HER2- readout or five years.
• Net proceeds earmarked mainly for paxalisib clinical development in TNBC, HR+/HER2- breast cancer, other oncology studies, working capital.
• Leerink Partners, Guggenheim Securities named joint bookrunners; offering size, pricing, timing not set.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-095310), on August 31, 2026, and is solely responsible for the information contained therein.